Bausch Health's new formulation of Xifaxan fails pair of Phase III trials [Yahoo! Finance]
Bausch Health Companies Inc. (BHC)
Last bausch health companies inc. earnings: 2/19 06:59 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The placebo-controlled trials evaluated the potential of amorphous-rifaximin solid soluble dispersion (SSD) to delay the onset of the first episode of HE in adults with liver cirrhosis – collectively enrolling more than 1,000 patients across 17 countries. In both the RED-C-3131 and RED-C-3132 studies (NCT05071716; NCT05297448), rifaximin SSD failed to significantly delay the first onset of HE in the treatment group compared with placebo, missing its primary endpoints. Bausch Health's stock value dropped by more than 10% from $6.57 at market close on 22 January to $5.91 at the same time on 23 January following the news debut. While Bausch divulged information about the drug's performance in primary endpoints, it remains unclear if the drug met any of its key secondary endpoints, which include time to all-cause hospitalisation and time to first confirmed overt hepatic encephalopathy (OHE) requiring medical intervention. HE is a common and severe neurological side effect of live
Show less
Read more
Impact Snapshot
Event Time:
BHC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHC alerts
High impacting Bausch Health Companies Inc. news events
Weekly update
A roundup of the hottest topics
BHC
News
- Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results [Yahoo! Finance]Yahoo! Finance
- Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention [Yahoo! Finance]Yahoo! Finance
- Has The Market Gone Too Far In Marking Down Bausch Health (BHC) Shares? [Yahoo! Finance]Yahoo! Finance
- Bausch Health Trial Miss Puts Liver Program And Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Bausch Health Cos (NYSE:BHC) had its "market perform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
BHC
Earnings
- 10/29/25 - Miss
BHC
Sec Filings
- 1/23/26 - Form 8-K
- 1/13/26 - Form 8-K
- 1/2/26 - Form 8-K
- BHC's page on the SEC website